Figure 6

RvD4 enhances human macrophage and dermal fibroblast phagocytosis and efferocytosis.

Isolated human macrophage were incubated with vehicle or RvD4 (10 pM-10 nM; 15 min, 37 °C) and then with (A) fluorescently labeled S. aureus (50:1); (B) FITC labeled opsonized zymosan A (10:1); or (C) fluorescent labeled apoptotic neutrophil for 1 hr (3:1). Results are mean ± SEM, n = 3 healthy subjects. *p < 0.05, **p < 0.01, ***p < 0.001 compared to vehicle. (D) Human-derived dermal fibroblasts were incubated with vehicle or RvD4 (1 pM-10 nM; 15 min, 37 °C), then with apoptotic neutrophil (3:1) for 1 hr; (E) Rank order comparison. Fibroblasts were incubated with RvD1, RvD4 or MaR1 (1nM; 15 min, 37 °C) with apoptotic neutrophils for 1 h and efferocytosis assessed. Results are mean ± SEM, n = 3–4. *p < 0.05, **p < 0.01 compared to vehicle.